Table 1.
Numbers of patients who tested positive on rectal swab surveillance in the study period based on microorganism isolated and susceptibility to ceftazidime-avibactam
| COVID-19 ICU patients n (%) [72 patients] |
Cardiac ICU patients n (%) [169 patients] |
Paediatric Onco-haematology Unit patients n (%) [110 patients] |
Other Departments patients n (%) [1488 patients] |
Total n (%) [1839 patients] |
|||
|---|---|---|---|---|---|---|---|
| KPC-producing Enterobacterales | CAZ-AVI susceptible | 2 (2.8) | 4 (2.4) | 1 (0.9) | 30 (2) | 37 (2) | |
| CAZ-AVI resistant | 22 (30.5) | 1 (0.6) | 0 | 12 (0.8) | 35 (1.9) | ||
| VIM-producing Enterobacterales | CAZ-AVI susceptible | 0 | 0 | 0 | 0 | 0 | |
| CAZ-AVI resistant | 0 | 0 | 2 (1.8) | 4 (0.3) | 6 (0.3) | ||
| NDM-producing Enterobacterales | CAZ-AVI susceptible | 0 | 0 | 0 | 0 | 0 | |
| CAZ-AVI resistant | 0 | 0 | 1 (0.9) | 3 (0.2) | 4 (0.2) | ||
| OXA-48-like-producing Enterobacterales | CAZ-AVI susceptible | 0 | 0 | 1 (0.9) | 2 (0.1) | 3 (0.2) | |
| CAZ-AVI resistant | 0 | 0 | 0 | 0 | 0 | ||
| KPC- and VIM-co-producing Enterobacterales | CAZ-AVI susceptible | 0 | 0 | 0 | 0 | 0 | |
| CAZ-AVI resistant | 4 (5.5) | 0 | 0 | 2 (0.1) | 6 (0.3) | ||
| Carbapenem-resistant non-carbapenemase producing-Enterobacterales | CAZ-AVI susceptible | 0 | 0 | 1 (0.9) | 2 (0.1) | 3 (0.2) | |
| CAZ-AVI resistant | 0 | 0 | 0 | 0 | 0 | ||
| Carbapenem-resistant A. baumannii complex | CAZ-AVI susceptible | 0 | 0 | 0 | 0 | 0 | |
| CAZ-AVI resistant | 6 (8.3) | 6 (3.5) | 1 (0.9) | 21 (1.4) | 34 (1.8) | ||
| VIM-producing P. aeruginosa | CAZ-AVI susceptible | 0 | 0 | 0 | 0 | 0 | |
| CAZ-AVI resistant | 0 | 0 | 0 | 2 (0.1) | 2 (0.1) | ||
| IMP-producing P. aeruginosa | CAZ-AVI susceptible | 0 | 0 | 0 | 0 | 0 | |
| CAZ-AVI resistant | 0 | 0 | 0 | 1 (0.07) | 1 (0.1) | ||
| Carbapenem-resistant non-metallo-β-lactamases producing P. aeruginosa | CAZ-AVI susceptible | 1 (1.4) | 3 (1.8) | 0 | 31 (2.1) | 35 (1.9) | |
| CAZ-AVI resistant | 0 | 2 (1.2) | 0 | 1 (0.07) | 3 (0.2) | ||